Trials Sponsors Conditions Drugs Pricing

Conditions

Acute Lymphoblastic Leukemia

Outcome Measures

Primary Outcomes (1)

Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Through study completion; an average of 1 year

Study Arms (2)

No TBI: No TBI Before CAR T Cell Infusion

EXPERIMENTAL

The Isoplexis Proteomics Platform will be used to interrogate up to 30 protein participants from single cells and bulk serum samples.

Drug: CAR T cell therapy

TBI: TBI 2 Gy Before CAR T Cell Infusion

EXPERIMENTAL

The Isoplexis Proteomics Platform will be used to interrogate up to 30 protein participants from single cells and bulk serum samples.

Drug: CAR T cell therapy

Interventions

CAR T cell therapyDrug

CAR T cell therapy will be administered as per the institutional guidelines and as per our standard of care

No TBI: No TBI Before CAR T Cell InfusionTBI: TBI 2 Gy Before CAR T Cell Infusion

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Patients must have a confirmed diagnosis of Acute Lymphoblastic Lymphoma and are planned to undergo CAT T cell therapy. The patient should not be planned to receive craniospinal irradiation prior to CAR T therapy; the latter group will be excluded from this study. Prior Radiation would not exclude patients from getting 2 Gy TBI, including prior TBI, in the event of a prior stem cell transplant.

Sponsors & Collaborators

M.D. Anderson Cancer Center
Otherlead

Study Sites (1)

UT MD Anderson

Houston, Texas, 77030, United States

Bouthaina Dabaja, MDCONTACT713-563-2406 bdabaja@mdanderson.org

Bouthaina Dabaja, MDPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

Immunotherapy, Adoptive

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

Study Officials

Bouthaina Dabaja, MD
UT MD Anderson
PRINCIPAL INVESTIGATOR

Central Study Contacts

Bouthaina Dabaja, MD

CONTACT

(713) 563-2406 bdabaja@mdanderson.org

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 29, 2026

First Posted

October 5, 2026

Study Start

March 1, 2027

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

July 1, 2028

Estimated

2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

No TBI: No TBI Before CAR T Cell Infusion

TBI: TBI 2 Gy Before CAR T Cell Infusion

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

No TBI: No TBI Before CAR T Cell Infusion

TBI: TBI 2 Gy Before CAR T Cell Infusion

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations